Skip to content
Head to head

Abivax S.A. vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ABVX · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ABVX -35.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
ABVXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price73.20515.02
Change today-9.24%-1.08%
1-year return-40.4%+22.0%
Market cap$6.41B$130.58B
52-week range62.70 – 148.83412.27 – 568.67
Valuation
P/E (TTM)-12.5233.14
P/E percentile, own 5-yr range55th99th
P/B15.956.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-5.3015.32
Net profit (TTM)$-463.71M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin-116091.3%85.5%
Operating margin-133443.5%33.1%
Net margin-138626.1%30.7%
Free cash flow (TTM)$-197.27M$3.20B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership114.8%96.8%
Insider activity (12mo)0 buy / 2 sell28 buy / 22 sell
Short interest (% of float)4.7%1.9%
Analyst consensus89% buy / 11% hold (9)95% buy / 5% hold (21)
Analyst price target$161 (+119%)$624 (+21%)
StockVane view
StockVane Quant RatingE (12)C (68)
Company
Employees696,400
Founded20031989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.